X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs VENUS REMEDIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH VENUS REMEDIES PANACEA BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x -16.2 -4.8 - View Chart
P/BV x 1.9 0.2 1,067.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
VENUS REMEDIES
Mar-18
PANACEA BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs149126 118.1%   
Low Rs8261 134.7%   
Sales per share (Unadj.) Rs84.1301.8 27.9%  
Earnings per share (Unadj.) Rs-18.3-24.9 73.6%  
Cash flow per share (Unadj.) Rs-6.72.5 -263.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7293.3 28.5%  
Shares outstanding (eoy) m61.2512.34 496.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.3 443.1%   
Avg P/E ratio x-6.3-3.8 167.8%  
P/CF ratio (eoy) x-17.236.7 -46.9%  
Price / Book Value ratio x1.40.3 432.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,154 613.1%   
No. of employees `0002.80.9 297.3%   
Total wages/salary Rs m1,449393 368.7%   
Avg. sales/employee Rs Th1,874.14,026.1 46.5%   
Avg. wages/employee Rs Th527.0425.0 124.0%   
Avg. net profit/employee Rs Th-407.7-331.8 122.9%   
INCOME DATA
Net Sales Rs m5,1543,724 138.4%  
Other income Rs m10023 443.6%   
Total revenues Rs m5,2543,747 140.2%   
Gross profit Rs m-766395 -194.1%  
Depreciation Rs m711338 210.2%   
Interest Rs m1,503354 424.2%   
Profit before tax Rs m-2,881-275 1,046.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1732 53.2%   
Profit after tax Rs m-1,121-307 365.4%  
Gross profit margin %-14.910.6 -140.3%  
Effective tax rate %-0.6-11.5 5.1%   
Net profit margin %-21.8-8.2 264.0%  
BALANCE SHEET DATA
Current assets Rs m3,8102,638 144.5%   
Current liabilities Rs m8,3652,305 363.0%   
Net working cap to sales %-88.48.9 -988.4%  
Current ratio x0.51.1 39.8%  
Inventory Days Days156135 115.0%  
Debtors Days Days6746 145.1%  
Net fixed assets Rs m14,4804,871 297.3%   
Share capital Rs m61123 49.7%   
"Free" reserves Rs m9033,496 25.8%   
Net worth Rs m5,1273,619 141.7%   
Long term debt Rs m5,8321,374 424.3%   
Total assets Rs m19,4337,509 258.8%  
Interest coverage x-0.90.2 -411.0%   
Debt to equity ratio x1.10.4 299.5%  
Sales to assets ratio x0.30.5 53.5%   
Return on assets %2.00.6 311.1%  
Return on equity %-21.9-8.5 257.9%  
Return on capital %3.61.6 229.8%  
Exports to sales %24.50-   
Imports to sales %10.213.9 73.4%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525517 101.6%   
Fx inflow Rs m1,5390-   
Fx outflow Rs m942517 182.4%   
Net fx Rs m597-517 -115.6%   
CASH FLOW
From Operations Rs m599514 116.5%  
From Investments Rs m-438-123 355.7%  
From Financial Activity Rs m-303-387 78.2%  
Net Cashflow Rs m-1414 -3,364.3%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.2 333.3%  
FIIs % 1.3 0.6 224.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 66.4 35.5%  
Shareholders   10,259 20,121 51.0%  
Pledged promoter(s) holding % 35.1 36.4 96.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 19, 2018 12:49 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - SUN PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS